Research Article
A Reappraisal of Women’s Health Initiative Estrogen-Alone Trial: Long-Term Outcomes in Women 50–59 Years of Age
Table 1
Women’s Health Initiative Estrogen-Alone Trial, age of participants in estrogen/placebo (intervention) phase of trial.
| ||||||||||||||||||||||||||||
A minority of participants were older at the end of the intervention phase than those listed in the upper limits of the estimated age brackets. (Start of intervention phase: December 1993; end of enrollment for intervention phase: October 1998; end of intervention phase: February 29, 2004; median duration of intervention phase: 7.2 years; end of reported trial follow-up: September 30, 2010 [1, 3].) bEstimates adjusted for age distribution of 50–59 y group (50–54 y/55–59 y = 1 : 1.37 ratio [14]) and for possible enrollment of participants at lower end of age bracket. cPercentages do not add to 100% because of rounding anomaly. CEE: conjugated equine estrogens; USA: United States of America. Derived from data provided in [1, 3, 14–19]. |